Endocrinology Medical News about peak bone mass;Peroxisome proliferator-activsted receptor gamma polymorphism

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

3. Rapid correction of low vitamin D status in nursing home residents

4. 2008 Exclusive Survey—Earnings: Good news for primary care income

5. Medicare pay-for-reporting effort draws fire from frustrated doctors

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Peroxisome proliferator-activated receptor gamma polymorphism is related to peak bone mass: The JPOS study
Osteoporosis International, 06/08/09

Tamaki J et al. – Study concludes that the peroxisome proliferator-activated receptors gamma (PPARγ) polymorphism C161T is associated with low peak bone mass.

Methods

Study examines the impact of PPARγ C161T polymorphism on bone mineral density (BMD) and its change
A baseline survey in 1996 and a 10-yr f/u survey
1,217 participants were analyzed cross-sectionally, while longitudinal analysis was performed on 563 women

Results

Total hip and femoral neck BMDs were higher for CC genotype than for CT/TT genotypes among 664 premenopausal women
Compared to the CC genotype, the odds ratio for osteopenia or osteoporosis at the femoral neck was 1.98 for premenopausal CT/TT genotypes
Change of BMD at either skeletal site during the f/u period was not different for either menstrual status

<< Previous
Statistical Tools to Analyze Continuous Glucose Monitor Data

Next >>
Stair Design in the United States and Obesity: The Need for a...